Health Care/Hospital

T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors

Summary * T-Maximum Pharmaceutical develops allogeneic CAR-T therapies with a unique CRISPR/Cas9 Gene-Editing platform for solid tumors, provide a solution of two major pain points, GvHD and HvG, aiming to revolutionize cancer. * MT027, the product of target B7H3 received US FDA orphan drug d...

2024-08-08 20:00 2172

MALAYSIA HEALTHCARE TRAVEL COUNCIL (MHTC) CONTINUES TO ENHANCE AND ELEVATE THEIR "EXPERIENCE MALAYSIA HEALTHCARE (EMH) STORIES" SERIES WITH EPISODE 3

KUALA LUMPUR, Malaysia, Aug. 8, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) continues their ongoing efforts to enhance and elevate their "Experience Malaysia Healthcare (EMH) Stories" with the third episode featuring Prof. Dato Sri Dr.Alwi Mohamed Yunus from Institut Jantung Ne...

2024-08-08 16:10 2655

WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

* Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ * Collaboration is a three-year and potentially multi-TCR p...

2024-08-08 16:00 1782

WestGene to Advance Clinical Trials Following Dual IND Approvals for World's First EB Virus-Related mRNA Therapeutic Cancer Vaccine

CHENGDU, China, Aug. 7, 2024 /PRNewswire/ -- WestGene Biopharma is proud to announce that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals fromChina's National Medical Products Administration (NMPA) and the US FDA. This unprecedented achievement marks the world's firs...

2024-08-08 10:59 1542

Morinaga Nutritional Foods Vietnam Promoting Sustainable Development with Advanced Technology, Unique functional ingredient, and Green Production

HANOI, Vietnam, Aug. 8, 2024 /PRNewswire/ -- Morinaga Nutritional Foods Vietnam (MNFV), an integral part of Morinaga Milk Industry Group - one of the leading company in the dairy and nutrition industry inJapan renowned for over a century of innovation and quality - embodies a commitment to excell...

2024-08-08 10:56 2439

Fierce Competition and Technological Innovation Drive Diabetes Care Devices Market Towards Explosive Growth

OEMs Leading the Charge with AI-Equipped Technology and Novel Business Strategies SAN ANTONIO, Aug. 8, 2024 /PRNewswire/ -- The diabetes care devices industry is witnessing a dynamic evolution, marked by intense competition among established players and emerging start-ups. Original Equipment Man...

2024-08-08 00:00 2008

PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells

Polyfunctionality correlates with a patient's remission lasting over 18 months with the CAR T cell  therapy IRVINE, Calif., Aug. 7, 2024 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies for cancers and immune disorders, today announced that City of...

2024-08-07 23:37 2593

Concord Medical Regains Compliance with NYSE Minimum Price Requirement

BEIJING, Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it has received a letter from the New York Stoc...

2024-08-07 20:30 3246

Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States

TAIPEI, Aug. 7, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. ("Eyenovia", NASDAQ: EYEN), whereby the companies will co-develop Clobetasol Propionate Ophthalmic Suspensi...

2024-08-07 20:00 2072

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, Md., Aug. 7, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) ("I-Mab", the "Company"), a U.S.-based, global biotech company, exclusively f...

2024-08-07 19:00 1303

Sanyou Pharmaceuticals and JiAnTeBo Biotechnology Forge Strategic Partnership to Jointly Develop New Agonist Antibody Drugs

SHANGHAI, Aug. 7, 2024 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Guangdong JiAnTeBo Biotechnology Co., Ltd. (hereinafter referred to as "JiAnTeBo")have signed a strategic cooperation agreement. Under the leadership of Professor Yi...

2024-08-07 18:00 1234

Docquity Drives Demand for SIT Pharma's Duo Probiotics in Thailand, Achieving 31% Sales Growth in 6 months

* Docquity's Awareness to Advocacy (A2A) Program and strong local distribution network enabled SIT's duo probiotic sales to surpass the market growth rate of 15% * The technology platform boosted SIT's HCP education efforts, more than doubling its reach to 2,000 HCPs within six months and aim...

2024-08-07 10:05 2279

GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

* Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2] * Latest published local registry reported endometrial cancer as the fourth most common cancer and had the ninth highest cancer mo...

2024-08-07 09:00 2208

Senhwa Biosciences receives US FDA Study May Proceed letter for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors

TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced receipt of a "Study May Proceed" letter from the U.S. Food and Drug A...

2024-08-07 08:49 2319

Datasea's Digital Technology Subsidiary Selected as Prospective Partner for Future Projects with Subsidiary of China Mobile

The Prospective Partnership with a Subsidiary of China Mobile, one of the World's Largest Mobile Operator, Underscores DTSS' Achievements in 5G-AI Communications BEIJING, Aug. 6, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorpora...

2024-08-06 21:30 2126

Lunit's AI for Tuberculosis Detection Tops in 12-Product Comparative Study

* Lancet Digital Health study highlights Lunit INSIGHT CXR as top performer in TB screening, showing promise for improving detection in high-burden settings SEOUL, South Korea, Aug. 6, 2024 /PRNewswire/ -- Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics,...

2024-08-06 21:00 1855

Antimicrobial Materials Sector Surges Amid Hygiene and Health Revolution

Pandemic-Driven Demand Shifts Focus to Safe, Durable, and Natural Compounds SAN ANTONIO, Aug. 6, 2024 /PRNewswire/ -- The antimicrobial materials industry is experiencing unprecedented growth, fuelled by a heightened focus on hygiene and cleanliness post-pandemic. Customers in the plastics, coati...

2024-08-06 21:00 2266

PHYLEX VACCINE ON TRACK TO COMBAT DEADLY NIPAH VIRUS WITH POSITIVE RESULTS OF IMMUNOGENICITY STUDY

DEL MAR, Calif., Aug. 6, 2024 /PRNewswire/ -- Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) inAtlant...

2024-08-06 20:00 1982

Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner

* Samsung Biologics to embed PSCI principles into business practices for responsible value chain management * Supplier Partnership reaffirms company's commitment to decarbonize and build resilient supply chains INCHEON, South Korea, Aug. 6, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940....

2024-08-06 19:00 1840

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...

2024-08-06 18:47 2117
1 ... 50515253545556 ... 847

Week's Top Stories